📣 VC round data is live. Check it out!
- Public Comps
- Giant Biogene
Giant Biogene Valuation Multiples
Discover revenue and EBITDA valuation multiples for Giant Biogene and similar public comparables like GSK India, Proya Cosmetics, Hengan Group, Unilever Indonesia and more.
Giant Biogene Overview
About Giant Biogene
Giant Biogene Holding Co Ltd design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenosides technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty and health properties such as skin repair, anti-aging, whitening, moisturizing and immunity improvement with a broad range of applications in the beauty and health sectors.
Founded
2021
HQ

Employees
1.8K
Website
Sectors
Financials (LTM)
EV
$3B
Valuation Multiples
Start free trialGiant Biogene Financials
Giant Biogene reported last 12-month revenue of $842M and EBITDA of $337M.
In the same LTM period, Giant Biogene generated $673M in gross profit, $337M in EBITDA, and $282M in net income.
Revenue (LTM)
Giant Biogene P&L
In the most recent fiscal year, Giant Biogene reported revenue of $816M and EBITDA of $360M.
Giant Biogene is profitable as of last fiscal year, with gross margin of 80%, EBITDA margin of 44%, and net margin of 35%.
Financial data powered by Morningstar, Inc.
Giant Biogene Stock Performance
Giant Biogene has current market cap of $4B, and enterprise value of $3B.
Market Cap Evolution
Giant Biogene's stock price is $3.69.
Giant Biogene share price decreased by 3.9% in the last 30 days, and by 49.9% in the last year.
Giant Biogene has an EPS (earnings per share) of $0.27.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $4B | -2.0% | -3.9% | 5.0% | -49.9% | $0.27 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGiant Biogene Valuation Multiples
Giant Biogene trades at 3.2x EV/Revenue multiple, and 8.0x EV/EBITDA.
EV / Revenue (LTM)
Giant Biogene Financial Valuation Multiples
As of June 3, 2026, Giant Biogene has market cap of $4B and EV of $3B.
Giant Biogene has a P/E ratio of 13.9x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Giant Biogene Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Giant Biogene Margins & Growth Rates
Giant Biogene grew revenue by 10% but EBITDA decreased by 4% in the last fiscal year.
In the most recent fiscal year, Giant Biogene reported gross margin of 80%, EBITDA margin of 44%, and net margin of 35%.
Giant Biogene Margins
Giant Biogene Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Giant Biogene Operational KPIs
Giant Biogene's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Giant Biogene's Rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Giant Biogene's Rule of X is 63% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Giant Biogene Competitors
Giant Biogene competitors include GSK India, Proya Cosmetics, Hengan Group, Unilever Indonesia, Fielmann Group, AmorePacific, Rohto Pharmaceutical, Procter & Gamble Hygiene, e.l.f. Beauty and Inter Parfums.
Most Giant Biogene public comparables operate across Health & Beauty.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 9.0x | 8.8x | 23.2x | 25.6x | |||
| 2.0x | 2.0x | 10.7x | 10.8x | |||
| 1.0x | 1.0x | 5.3x | 5.8x | |||
| 1.7x | 1.7x | 11.0x | 10.7x | |||
| 1.8x | 1.7x | 7.5x | 7.4x | |||
| 1.4x | 1.3x | 9.5x | 9.2x | |||
| 1.6x | 1.4x | 8.8x | 8.4x | |||
| 6.8x | 6.7x | 24.6x | 24.8x | |||
This data is available for Pro users. Sign up to see all Giant Biogene competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Giant Biogene
| When was Giant Biogene founded? | Giant Biogene was founded in 2021. |
| Where is Giant Biogene headquartered? | Giant Biogene is headquartered in China. |
| How many employees does Giant Biogene have? | As of today, Giant Biogene has over 1K employees. |
| Who is the CEO of Giant Biogene? | Giant Biogene's CEO is Jianya Yan. |
| Is Giant Biogene publicly listed? | Yes, Giant Biogene is a public company listed on HKEX. |
| What is the stock symbol of Giant Biogene? | Giant Biogene trades under 02367 ticker. |
| When did Giant Biogene go public? | Giant Biogene went public in 2022. |
| Who are competitors of Giant Biogene? | Giant Biogene main competitors include GSK India, Proya Cosmetics, Hengan Group, Unilever Indonesia, Fielmann Group, AmorePacific, Rohto Pharmaceutical, Procter & Gamble Hygiene, e.l.f. Beauty, Inter Parfums. |
| What is the current market cap of Giant Biogene? | Giant Biogene's current market cap is $4B. |
| What is the current revenue of Giant Biogene? | Giant Biogene's last 12 months revenue is $842M. |
| What is the current revenue growth of Giant Biogene? | Giant Biogene revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Giant Biogene? | Current revenue multiple of Giant Biogene is 3.2x. |
| What is the current EBITDA of Giant Biogene? | Giant Biogene's last 12 months EBITDA is $337M. |
| What is Giant Biogene's EBITDA margin? | Giant Biogene's last 12 months EBITDA margin is 40%. |
| What is the current EV/EBITDA multiple of Giant Biogene? | Current EBITDA multiple of Giant Biogene is 8.0x. |
| What is the current FCF of Giant Biogene? | Giant Biogene's last 12 months FCF is $238M. |
| What is Giant Biogene's FCF margin? | Giant Biogene's last 12 months FCF margin is 28%. |
| What is the current EV/FCF multiple of Giant Biogene? | Current FCF multiple of Giant Biogene is 11.3x. |
| How many companies Giant Biogene has acquired to date? | Giant Biogene hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Giant Biogene has invested to date? | Giant Biogene hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Giant Biogene
Lists including Giant Biogene
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.